Pegylated Interferon-based Treatment Improves Response Rates in Immune-tolerant Patients with Chronic Hepatitis B: A Prospective Trial. [PDF]
Liu M +10 more
europepmc +1 more source
SEROLOGICAL CLEARANCE OF HBSAG IN CHRONIC HEPATITIS B: EXPERIENCE IN A UNIVERSITY HOSPITAL. [PDF]
Amorim AGG, Costa APM.
europepmc +1 more source
Hepatitis B Virus: Epidemiology, Prophylaxis, Therapy, Clinical Outcomes, and Novel Therapeutic Directions. [PDF]
Iqbal U +7 more
europepmc +1 more source
Altered expression of MX2 and SAMD4A in PBMCs predicts early treatment responses in HBeAg-positive chronic hepatitis B patients during Peg-IFN-α therapy. [PDF]
Pang H, Zhang Q, Chen L, Qin B.
europepmc +1 more source
Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy. [PDF]
Michler T +9 more
europepmc +1 more source
Efficacy and Metabolic Effects of Pegylated Interferon α-2b versus Nucleos(T)ide Analogues in Patients with Chronic Hepatitis B and Concomitant Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Study. [PDF]
Liu Y +9 more
europepmc +1 more source
Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study. [PDF]
Gong H +10 more
europepmc +1 more source
[Spontaneous seroconversion of HBeAg into anti-HBe in patients with chronic hepatitis B].
N, Hadzić +4 more
openaire +1 more source
Chemical Design and Therapeutic Efficacy of HBsAg-Based Nanovaccines for Hepatitis B Virus Clearance: A Preclinical and Clinical Systematic Review. [PDF]
Nequi Marnani H +6 more
europepmc +1 more source
Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease. [PDF]
Zhu C, Yang J, Sheng Y, Fang M.
europepmc +1 more source

